Get the Stockscreener App
6.1811
7.61%
-0.5089
Bluebird Bio Inc stock is traded at $6.1811, with a volume of 264.70K.
It is down -7.61% in the last 24 hours and down -31.47% over the past month.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
See More
Previous Close:
$6.69
Open:
$6.86
24h Volume:
264.70K
Relative Volume:
0.67
Market Cap:
$65.04M
Revenue:
$21.73M
Net Income/Loss:
$-91.17M
P/E Ratio:
-8.3528
EPS:
-0.74
Net Cash Flow:
$-286.43M
1W Performance:
-20.24%
1M Performance:
-31.47%
6M Performance:
-67.22%
1Y Performance:
-66.97%
1-Day Range:
$6.10
$6.92
1-Week Range:
$6.10
$7.55
52-Week Range:
$5.80
$38.40
Bluebird Bio Inc Stock (BLUE) Company Profile
Name
Bluebird Bio Inc
Sector
Industry
Phone
339-499-9300
Address
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Compare BLUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
6.19 | 65.04M | 21.73M | -91.17M | -286.43M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.62 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.80 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.26 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.52 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.28 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-15-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-11-23 | Downgrade | HSBC Securities | Hold → Reduce |
| Dec-08-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-17-23 | Initiated | Cantor Fitzgerald | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-19-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-01-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-28-23 | Initiated | JP Morgan | Overweight |
| Mar-07-23 | Initiated | Robert W. Baird | Outperform |
| Aug-05-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-02-22 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-06-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-07-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Nov-08-21 | Reiterated | Barclays | Equal Weight |
| Nov-08-21 | Reiterated | Canaccord Genuity | Hold |
| Nov-08-21 | Downgrade | Goldman | Neutral → Sell |
| Nov-08-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Nov-08-21 | Reiterated | Wedbush | Neutral |
| Nov-08-21 | Reiterated | Wells Fargo | Equal Weight |
| Aug-10-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-10-21 | Downgrade | Goldman | Buy → Neutral |
| Aug-10-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-10-21 | Resumed | William Blair | Mkt Perform |
| Aug-09-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-01-21 | Downgrade | Berenberg | Buy → Hold |
| Mar-10-21 | Upgrade | Mizuho | Neutral → Buy |
| Feb-17-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-16-21 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-16-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-09-20 | Downgrade | Maxim Group | Buy → Hold |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-05-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-05-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Nov-05-20 | Downgrade | Stifel | Buy → Hold |
| Nov-02-20 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-20-20 | Initiated | Mizuho | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-27-20 | Upgrade | Stifel | Hold → Buy |
| Feb-19-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Feb-03-20 | Resumed | BofA/Merrill | Buy |
| Feb-03-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-13-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-19-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-04-19 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-01-19 | Initiated | Stifel | Hold |
| Aug-12-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-18-19 | Upgrade | Maxim Group | Hold → Buy |
View All
Bluebird Bio Inc Stock (BLUE) Latest News
bluebird bio, Inc. (NASDAQ:BLUE) Sees Large Drop in Short Interest - MarketBeat
Car T Cell Therapy Market Projected To Witness Substantial Growth, 2025-2032 | Pfizer, bluebird bio, Johnson & - EIN News
bluebird bio, Inc. (NASDAQ:BLUE) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Bluebird bio's chief commercial officer Klima sells $901 in stock - MSN
Bluebird bio chief business officer Joseph Vittiglio sells $1,759 in stock - MSN
Bluebird bio chief medical officer sells $473 in stock By Investing.com - Investing.com South Africa
Bluebird bio chief medical officer sells $473 in stock - MSN
Bluebird bio chief business officer Joseph Vittiglio sells $1,759 in stock By Investing.com - Investing.com South Africa
CAR T-Cell Therapy Market Forecasts to 2035, with Competitor Profiles of Autolus, Bluebird Bio, Carsgen Therapeutics, Cellectis, Noile-Immune Biotech, Shanghai GeneChem, Takara Bio and More - Yahoo Finance UK
IMMINENT BLUE DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds bluebird bio, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
BLUE (bluebird bio) Dividends per Share : $0.00 (TTM As of Sep. 2024) - GuruFocus.com
bluebird bio (NASDAQ:BLUE) Shares Cross Below 200 Day Moving AverageTime to Sell? - MarketBeat
BLUE (bluebird bio) Operating Income : $-318.48 Mil (TTM As of Sep. 2024) - GuruFocus.com
bluebird (BLUE) Underperforms Industry YTD Amid Challenges - MSN
BLUE (bluebird bio) Earnings per Share (Diluted) : $-35.80 (TTM As of Sep. 2024) - GuruFocus.com
Sickle Cell Treatment Market Focusing on Trends and Innovations - openPR
bluebird bio Q4 EPS Estimate Increased by Leerink Partnrs - MarketBeat
Cantor Fitzgerald Predicts bluebird bio FY2025 Earnings - MarketBeat
Sickle Cell Disease Pipeline 2024: Comprehensive Clinical - openPR
Bluebird Bio presents long-term data on LYFGENIA gene therapy for SCD - MSN
Cantor Fitzgerald Estimates bluebird bio FY2025 Earnings - MarketBeat
Long-Term Investors in bluebird bio Inc (NASDAQ: BLUE) should - openPR
bluebird bio, Inc. (NASDAQ:BLUE) Short Interest Update - MarketBeat
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Adrenoleukodystrophy Drugs Market Is Booming Worldwide - openPR
Brokerages Set bluebird bio, Inc. (NASDAQ:BLUE) PT at $49.14 - Defense World
FDA investigating safety risks of bluebird's Skysona - MSN
bluebird bio, Inc. (NASDAQ:BLUE) Given Consensus Rating of "Hold" by Analysts - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) & bluebird bio (NASDAQ:BLUE) Head-To-Head Survey - Defense World
National Resilience to lay off 120 in North Carolina - Manufacturing Dive
Bluebird bio CEO Andrew Obenshain sells $1,293 in stock By Investing.com - Investing.com Nigeria
Bluebird bio chief medical officer sells $175 in stock By Investing.com - Investing.com Australia
Bluebird bio CEO Andrew Obenshain sells $1,293 in stock - Investing.com
Bluebird bio chief medical officer sells $175 in stock - Investing.com
bluebird bio (NASDAQ:BLUE) Stock Price Passes Below 200-Day Moving AverageHere's Why - MarketBeat
Gene Therapy Market Generated Opportunities, Future Scope by 2031 | GlaxoSmithKline plc, Bluebird Bio, Inc. - openPR
CDMO National Resilience plots 120 layoffs at former bluebird bio facility in Research Triangle Park - FiercePharma
Biotech manufacturer plans to cut 120 jobs in Durham - WRAL News
Hemoglobinopathies Market Projected to Show Strong Growth| - openPR
Gene Therapy Market Generated Opportunities, Future Scope - openPR
Investors Don't See Light At End Of bluebird bio, Inc.'s (NASDAQ:BLUE) Tunnel And Push Stock Down 38% - Simply Wall St
Barclays Issues Positive Forecast for bluebird bio (NASDAQ:BLUE) Stock Price - Defense World
bluebird bio's SWOT analysis: gene therapy stock faces cash crunch amid launch - Investing.com
Barclays Forecasts Strong Price Appreciation for bluebird bio (NASDAQ:BLUE) Stock - MarketBeat
bluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now? - Insider Monkey
Bluebird Bio Inc Stock (BLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bluebird Bio Inc Stock (BLUE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Colvin Richard A | Chief Medical Officer |
Feb 03 '25 |
Sale |
7.39 |
64 |
473 |
8,194 |
| Vittiglio Joseph | Chief Business & Legal Officer |
Feb 03 '25 |
Sale |
7.39 |
238 |
1,759 |
4,501 |
| Obenshain Andrew | President and CEO |
Feb 03 '25 |
Sale |
7.39 |
86 |
636 |
18,485 |
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):